ClinicalTrials.gov
skipnavHome|Search|Browse|Resources|Help|What's New|About

Matrix metalloproteinases and Diabetic Nephropathy

This study is currently recruiting patients.

Sponsored by: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Information provided by: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Purpose

Matrix metalloproteinases (MMPs) are a family of protein-degrading enzymes that are involved in the breakdown and remodeling of many tissues and organs. Abnormal activity of these enzymes has been implicated in many disease processes including rheumatoid arthritis, dental disease and metastatic cancer. Recent studies also suggest that elevations in blood sugar may abnormally effect MMP enzyme activity. Decreased activity of some of these MMP enzymes may be a partial cause of the abnormal enlargement of the kidney (renal hypertrophy) seen at the start of diabetic kidney disease (nephropathy). Preliminary clinical data from our laboratory confirm that children with newly diagnosed type 1 diabetes mellitus (DM) have lower blood levels of some of these enzymes at the time of very high blood sugar readings. However, these enzyme levels become normal again as blood sugar levels improve with insulin treatment. In the present study, we propose to investigate the hypothesis that MMPs are involved in the cause of diabetic kidney disease by measuring concentrations of specific MMPs and some related proteins in the blood and urine of patients with type 1 DM who are between the ages of 14-40 years. We will enroll some patients who are recently diagnosed with diabetes, some who have had diabetes for several years, but without signs of kidney disease, and some with long-term diabetes and various degrees of kidney disease. Continuous Subcutaneous Glucose Monitoring, conducted for 3-4 days, will also be provided as a part of this study, to determine how different levels of blood sugar control might relate to different levels of MMP enzyme activity in the blood. We anticipate that this study will help to establish a link between abnormal MMP activity and the cause of nephropathy in type 1 DM, allowing scientists to design better therapies for the prevention and treatment of diabetes-related kidney problems.

Condition
Diabetes Mellitus, Type 1
Diabetic Nephropathy

MedlinePlus related topics:  Diabetic Kidney Problems;   Juvenile Diabetes

Study Type: Observational
Study Design: Screening, Cross-Sectional, Defined Population, Prospective Study

Further Study Details: 

Expected Total Enrollment:  330

Study start: March 2003

Eligibility

Ages Eligible for Study:  14 Years   -   40 Years,  Genders Eligible for Study:  Both

Accepts Healthy Volunteers

Criteria

Type 1 Diabetes with or without kidney disease and past puberty.

Location and Contact Information


Arkansas
      Arkansas Children's Hospital/University of Arkansas for Medical Sciences, Little Rock,  Arkansas,  72202,  United States; Recruiting
Cynthia S Moreau, RN  501-364-1975    moreaucynthias@uams.edu 
Kathy Edwards, RN  501-364-1430 

More Information

Study ID Numbers:  MMADN
Record last reviewed:  August 2004
Record first received:  August 29, 2003
ClinicalTrials.gov Identifier:  NCT00067886
Health Authority: United States: Federal Government
ClinicalTrials.gov processed this record on 2004-10-27
line
U.S. National Library of Medicine, Contact NLM Customer Service
National Institutes of Health, Department of Health & Human Services
Copyright, Privacy, Accessibility, Freedom of Information Act